<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047254</url>
  </required_header>
  <id_info>
    <org_study_id>2007-005352-17</org_study_id>
    <nct_id>NCT01047254</nct_id>
  </id_info>
  <brief_title>Bupropion for the Treatment of Apathy in Alzheimer's Dementia</brief_title>
  <acronym>APA-AD</acronym>
  <official_title>A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy in dementia prevents successful application of non-pharmacological treatments,&#xD;
      accelerates cognitive and functional decline and increases disease-related costs by earlier&#xD;
      need for full-time care. Apathy is a distinct entity and occurs independently of other&#xD;
      neuropsychiatric syndromes, like depression.&#xD;
&#xD;
      Today, there is no high-level evidence for any effective treatment of apathy in AD. In&#xD;
      contrast to other neuropsychiatric syndromes in AD, like psychosis and depression, and&#xD;
      despite its high prevalence and clinical relevance, apathy has never been the primary outcome&#xD;
      in a clinical trial. Basic and clinical research has provided a distinct model of the&#xD;
      pathophysiology of apathy with dopamine and norepinephrine as the key neurotransmitter&#xD;
      systems involved. The antidepressant Bupropion is a dopamine and norepinephrine reuptake&#xD;
      inhibitor. There is evidence from case-series, that Bupropion reduces apathy in patients with&#xD;
      organic brain disorders. This study will test the efficacy and safety of Bupropion in the&#xD;
      treatment of apathy in AD in a 12-week multicenter doubleblind placebo controlled trial.&#xD;
      Secondary endpoints will be quality of life of patients, caregivers' distress, ability of&#xD;
      patients to perform activities of daily living,utilization of healthcare resources by&#xD;
      patients and by caregivers, and cognitive functions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apathy Evaluation Scale (AES) score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Apathy in Dementia</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buproprion 150-300 mg in a flexible dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elontril</intervention_name>
    <description>flexible dose of Bupropion 150-300 mg</description>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to moderate Alzheimer's dementia, male and female (NINCDS/ADRDA criteria)&#xD;
&#xD;
          -  Presence of clinically relevant apathy defined by the Neuropsychiatric Inventory (NPI)&#xD;
             apathy item (score of &gt;/= 4 points) and the Marin/Starkstein criteria for apathy&#xD;
&#xD;
          -  MMSE: 10-25&#xD;
&#xD;
          -  Outpatient status, not institutionalized&#xD;
&#xD;
          -  Presence of reliable caregiver&#xD;
&#xD;
          -  Stable treatment with antidementia drugs for at least three months prior to entry or&#xD;
             no treatment with antidementia drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other Dementia (e.g. vascular dementia, Lewy-body dementia, fronto-temporal dementia)&#xD;
&#xD;
          -  Presence of a clinically relevant depression defined by either the NPI depression item&#xD;
             (score &gt;/= 4 points) or DSM-IV criteria for major depressive episode (with depressed&#xD;
             mood)&#xD;
&#xD;
          -  Alcoholism and Benzodiazepine addiction&#xD;
&#xD;
          -  Current treatment with antipsychotics and antidepressants (including St. John's wart)&#xD;
&#xD;
          -  Current treatment with dopaminergic agents or Amantadin&#xD;
&#xD;
          -  Current treatment with benzodiazepines&#xD;
&#xD;
          -  Current treatment with MAO inhibitor (Bupropion contraindication)&#xD;
&#xD;
          -  Known sensibility to Bupropion treatment&#xD;
&#xD;
          -  Severe psychiatric disease (including hospitalization) in the last 6 months, suicide&#xD;
             attempt, acute psychotic symptoms&#xD;
&#xD;
          -  Severe physical illness, that do not allow a participation in a 12-week period of&#xD;
             treatment&#xD;
&#xD;
          -  Medical history with seizures&#xD;
&#xD;
          -  Medical history with tumors of the central nervous system&#xD;
&#xD;
          -  Severe craniocerebral injury and medical history with cerebral substance defect&#xD;
&#xD;
          -  Clinically relevant renal disease, liver insufficiency&#xD;
&#xD;
          -  Simultaneous treatment, which reduces the seizure threshold (e.g. antipsychotics,&#xD;
             antidepressants, antimalarial agents, Tramadol, Theophyllin, systemic steroids in&#xD;
             higher dose, Chinolone, sedative antihistamines)&#xD;
&#xD;
          -  Simultaneous treatment, which is metabolized through Cytochrom P450-Isoenzym 2D6 (e.g.&#xD;
             these beta blockers: Metoprolol, Proanolol, Timolol, Carvediol, Nebivolol,&#xD;
             Typ-1C-Antiarrhyhtmics for e.g. Propafenon, Flecinid) (except Donepezil and&#xD;
             Galantamin)&#xD;
&#xD;
          -  Simultaneous treatment with drugs, which may interfere with the metabolization of&#xD;
             Bupropion (e.g. Carbamazepin, Phenytoin, Valproat, Ritonavir, Lopinavir)&#xD;
&#xD;
          -  Diabetes mellitus, which is therapeutically poorly regulated and treated by medication&#xD;
&#xD;
          -  Treatment with stimulants and appetite depressants&#xD;
&#xD;
          -  Participation in other clinical trials with in the last 3 months&#xD;
&#xD;
          -  Suicidal tendency&#xD;
&#xD;
          -  Known lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Jessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank Jessen</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

